First human trial tests promising new cancer drug combo
NCT ID NCT06462794
Summary
This is the first human study of an experimental cancer drug called CX-801. Researchers are testing it alone and combined with an existing immunotherapy drug (pembrolizumab) in 121 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe dose levels and see if the treatment shows early signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
University of Pittsburgh Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.